ZIVO Bioscience Announces Uplisting to OTCQB Market
29 Janeiro 2024 - 10:00AM
Business Wire
Zivo Bioscience, Inc. (OTCQB: ZIVO) (the “Company”), a
biotech/agtech R&D company engaged in the development of
therapeutic, medicinal and nutritional product candidates derived
from proprietary algal cultures, announces it has uplisted the
trading of shares of its common stock from the OTC® Pink Market to
the OTCQB® Venture Market (OTCQB), effective as of the opening of
trading on Friday, January 26, 2024. Following this uplisting, ZIVO
Bioscience continues to trade under the ticker symbol “ZIVO” and
warrants continue to trade under the ticker symbol “ZIVOW”.
“In line with our strategic objectives, we have successfully
completed the transition of our shares to the OTCQB market. This
move is a direct result of our commitment to transparency and our
goal to enhance our visibility in the market, and is a step toward
listing our shares on a larger, more accessible exchange. The OTCQB
market has increased compliance and quality standards, broadens
access and may improve liquidity for shareholders. We are confident
this step will expand ZIVO Bioscience's visibility and attract a
wider range of investors,” said John Payne, Chairman and Chief
Executive Officer of ZIVO Bioscience.
The OTCQB, operated by OTC Markets Group, Inc., is designed for
developing and entrepreneurial companies in the United States and
abroad and is committed to providing investors with improved market
visibility to enhance trading liquidity. To be eligible for trading
on the OTCQB, companies must be current in their financial
reporting with the Securities and Exchange Commission ("SEC") or
OTC Markets Group, Inc., pass a minimum bid price test, maintain
audited financials through a PCAOB registered firm, and undergo
company verification and management certification on an annual
basis.
The OTCQB is operated by the OTC Markets Group and is recognized
by the SEC as an established public market providing data that
investors need to analyze, value and trade securities.
About ZIVO Bioscience
ZIVO Bioscience is a research and development company with an
intellectual property portfolio comprised of proprietary algal and
bacterial strains, biologically active molecules and complexes,
production techniques, cultivation techniques and patented or
patent pending inventions for applications in human and animal
health. Please visit www.zivobioscience.com for more
information.
Forward Looking Statements
Except for any historical information, the matters discussed in
this press release contain forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933 and Section
21E of the Securities Exchange Act of 1934, including with respect
to the Company’s product candidate’s potential to generate revenues
and the expected time frame for results of future studies. Words
such as "expects," "anticipates," "intends," "plans," "believes,"
"seeks," "estimates" and similar expressions or variations of such
words are intended to identify forward-looking statements. Although
ZIVO believes that we have a reasonable basis for each
forward-looking statement, we caution you that these statements are
based on a combination of facts and factors currently known by us
and our expectations of the future, about which we cannot be
certain. Our actual future results may be materially different from
what we expect due to factors largely outside our control,
including risks that our strategic partnerships may not facilitate
the commercialization or market acceptance of our products; risks
that we will be unable to increase production sufficient to meet
our expected demand; risks that our products may not be ready for
commercialization in a timely manner or at all; risks that our
products will not perform as expected based on results of our
pre-clinical and clinical trials; our ability to raise additional
funds; uncertainties inherent in the development process of our
products; changes in regulatory requirements or decisions of
regulatory authorities; the size and growth potential of the
markets for our products; the results of clinical trials, our
ability to protect our intellectual property rights and other
risks, uncertainties and assumptions, including those described
under the heading “Risk Factors” in our filings with the Securities
and Exchange Commission. These forward–looking statements speak
only as of the date of this press release and ZIVO undertakes no
obligation to revise or update any forward–looking statements for
any reason, even if new information becomes available in the
future.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240129692085/en/
ZIVO Bioscience Keith Marchiando, Chief Financial Officer
(248) 452-9866 x130 kmarchiando@zivobioscience.com
LHA Investor Relations Tirth T. Patel (212) 201-6614
tpatel@lhai.com
Zivo Bioscience (NASDAQ:ZIVO)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Zivo Bioscience (NASDAQ:ZIVO)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024